Molecular Diagnosis & Therapy

, Volume 15, Issue 6, pp 341–346 | Cite as

Evaluation of a Tuberculosis Whole-Blood Interferon-γ Chemiluminescent Immunoassay among Chinese Military Recruits

  • Xueqiong Wu
  • Ying Hou
  • Yan Liang
  • Junxian Zhang
  • Yourong Yang
  • Lan Wang
  • Chuiying Zhang
Original Research Article


Background and Objective: China is a country with a high prevalence of latent tuberculosis (TB) infection (LTBI) and has a policy of routine bacillus Calmette-Guérin (BCG) vaccination. The purified protein derivative (PPD) skin test cannot distinguish TB infection from BCG vaccination, and the diagnosis of LTBI lacks an accepted standard method. The primary objective of this study was to assess the potential of a highly sensitive whole-blood interferon (IFN)-γ release assay that uses recombinant culture filtrate protein (CFP)-10/early secretory antigenic target (ESAT)-6 fusion protein (rCFP-10/ESAT-6) as a stimulus for diagnosis of LTBI.

Methods: Between December 2009 and March 2010, a total of 892 new recruits to the army in Beijing, China, were interviewed and routinely examined by chest radiographs. IFNγ released from whole blood in response to stimulation with rCFP-10/ESAT-6 was detected with an enzyme-linked chemiluminescent immunoassay. The recruits were also intradermally injected with PPD to assess 72-hour skin induration (the PPD skin test).

Results: Of the 892 participants, 450 (50.4%) had a positive PPD skin test and 244 (27.4%) had a positive whole-blood IFNγ release assay. Of 442 PPD-negative subjects, 88 (19.9%) had a positive whole-blood IFNγ test. Of 450 PPD-positive subjects, 156 (34.7%) had a positive whole-blood IFNγ test. Of 132 strongly PPD- positive subjects, 62 (47.0%) had a positive whole-blood IFNγ test. The agreement between the two tests was 57.2%. Of the 892 participants, 579 (64.9%) had clear vaccination scars on their arms, and of these, 382 (66.0%) had positive PPD skin responses and 162 (28.0%) were positive for the whole-blood IFNγ test.

Conclusion: The new whole-blood IFNγ release assay might be a better indicator of LTBI than the PPD test in China.


Tuberculin Skin Test Purify Protein Derivative Chemiluminescent Immunoassay Skin Induration Early Secretory Antigenic Target 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by the Serious Infectious Diseases Special Foundation of China (grant no. 2008ZX-10003-001) and the National Nature and Science Foundation of China (grant no. 30471648). The authors have no conflicts of interest that are directly relevant to the content of this study.


  1. 1.
    National Technical Steering Group of the Epidemiological Sampling Survey for Tuberculosis. Report on Fourth National Epidemiological Sampling Survey of Tuberculosis [in Chinese]. Chin J Tuberc Respir Dis 2002; 25: 3–7Google Scholar
  2. 2.
    Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005; 293: 2756–61PubMedCrossRefGoogle Scholar
  3. 3.
    Lee JY, Choi HJ, Park IN, et al. Comparison of two commercial interferon-γ assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006; 28: 24–30PubMedCrossRefGoogle Scholar
  4. 4.
    Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367: 1328–34PubMedCrossRefGoogle Scholar
  5. 5.
    Mazurek GH, Weis SE, Moonan PK, et al. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-γ release assays in persons with suspected tuberculosis. Clin Infect Dis 2007; 45: 837–45PubMedCrossRefGoogle Scholar
  6. 6.
    Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole genome DNA microarray. Science 1999; 284: 1520–3PubMedCrossRefGoogle Scholar
  7. 7.
    Behr MA. Comparative genomics of BCG vaccines. Tuberculosis 2001; 81: 165–8PubMedCrossRefGoogle Scholar
  8. 8.
    Harboe M, Oettinger T, Wiker HG, et al. Evidence for occurrence of the ESAT6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 1996; 64: 16–22PubMedGoogle Scholar
  9. 9.
    Porsa E, Cheng L, Graviss EA. Comparison of an ESAT-6/CFP-10 peptide-based enzyme-linked immunospot assay to a tuberculin skin test for screening of a population at moderate risk of contracting tuberculosis. Clin Vaccine Immunol 2007; 14: 714–9PubMedCrossRefGoogle Scholar
  10. 10.
    Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-γ-based assay using new antigens. Am J Respir Crit Care Med 2004; 170: 59–64PubMedCrossRefGoogle Scholar
  11. 11.
    Goletti D, Vincenti D, Carrara S, et al. Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. Clin Diagn Lab Immun 2005; 12: 1311–6Google Scholar
  12. 12.
    Brock I, Munk ME, Kok-Jensen A, et al. Performance of whole blood IFN-γ test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10. Int J Tuberc Lung Dis 2001; 5: 462–7PubMedGoogle Scholar
  13. 13.
    Brock I, Weldingh K, Lillebaek T, et al. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004; 170: 65–9PubMedCrossRefGoogle Scholar
  14. 14.
    Wu X, Li Q, Yang Y, et al. Latent tuberculosis infection among new soldiers in Chinese army: comparison of ELISPOT assay and tuberculin skin test. Clinica Chimica Acta 2009; 405: 110–3CrossRefGoogle Scholar
  15. 15.
    Alkana S, Akdisa C, Towbina H. Immuno assays for sensitive detection of human IFN-γ. J Immunoass Immunoch 1994; 15: 217–38CrossRefGoogle Scholar
  16. 16.
    Olesen CEM, Voyta JC, Bronstein I. Chemiluminescent immunoassay for the detection of chloramphenicol acetyltransferase and human growth hormone reporter proteins. Method Mol Biol 1997; 63: 71–6Google Scholar
  17. 17.
    Singh AK. Evaluation of solid-phase chemiluminescent enzyme immunoassay, enzyme-linked immunosorbent assay, and latex agglutination tests for screening toxoplasma IgG in samples obtained from cats and pigs. J Vet Diagn Invest 2000; 12: 136–41PubMedCrossRefGoogle Scholar
  18. 18.
    Basso D, Guariso G, Fasolo M, et al. A new indirect chemiluminescent immunoassay to measure anti-tissue transglutaminase antibodies. J Pediatr Gastr Nutr 2006; 43: 613–8CrossRefGoogle Scholar
  19. 19.
    Pai M, Riley LW, Colford Jr JM. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004; 4: 761–76PubMedCrossRefGoogle Scholar
  20. 20.
    Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn 2006; 6: 413–22PubMedCrossRefGoogle Scholar
  21. 21.
    Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection. An update. Ann Intern 2008; 149: 177–84Google Scholar
  22. 22.
    Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon-γ assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005; 293: 2756–61PubMedCrossRefGoogle Scholar
  23. 23.
    Kimura M, Converse PJ, Astemborski J, et al. Comparison between a whole blood interferon-γ release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure. J Infect Dis 1999; 179: 1297–300PubMedCrossRefGoogle Scholar
  24. 24.
    Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361: 1168–73PubMedCrossRefGoogle Scholar
  25. 25.
    Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: 1192–204PubMedGoogle Scholar
  26. 26.
    Van Pinxteren LA, Ravn P, Agger EM, et al. Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin Diagn Lab Immunol 2000; 7: 155–60Google Scholar
  27. 27.
    Hill PC, Jackson-Sillah D, Fox A, et al. ESAT-6/CFP-10 fusion protein and peptides for optimal diagnosis of Mycobacterium tuberculosis infection by ex vivo enzyme-linked immunospot assay in the Gambia. J Clin Microbiol 2005; 43: 2070–4PubMedCrossRefGoogle Scholar
  28. 28.
    Mori T, Harada N, Higuchi K, et al. Waning of the specific interferon-gamma response after years of tuberculosis infection. Int J Tuberc Lung Dis 2007; 11: 1021–5PubMedGoogle Scholar
  29. 29.
    Dheda K, Udwadia ZF, Huggett JF, et al. Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med 2005; 11: 195–202PubMedCrossRefGoogle Scholar
  30. 30.
    Diel R, Nienhaus A, Lange C, et al. Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir Res 2006; 7: 77PubMedCrossRefGoogle Scholar
  31. 31.
    Andersen P, Doherty TM, Pai M, et al. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med 2007; 13: 175–82PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Xueqiong Wu
    • 1
  • Ying Hou
    • 1
  • Yan Liang
    • 1
  • Junxian Zhang
    • 1
  • Yourong Yang
    • 1
  • Lan Wang
    • 1
  • Chuiying Zhang
    • 1
  1. 1.Army Tuberculosis Prevention and Control Key LaboratoryInstitute of Tuberculosis ResearchBeijingChina

Personalised recommendations